 CRESSKILL, N.J. and JERUSALEM, Israel, Aug. 12, 2020 GLOBE NEWSWIRE -- BrainsWay Ltd. NASDAQ TASE: BWAY BrainsWay or the Company, a global leader in the advanced non-invasive treatment of brain disorders, today reported financial results for the quarter ended June 30, 2020, and provided an operational update. Recent Financial and Operational Highlights For the three months ended June 30, 2020, the impact of the temporary shutdown of certain physician offices due to COVID-19 resulted in revenues of 4.8 million, a decrease of 15 as compared to the same period of 2019. As of June 30, 2020, BrainsWays Deep TMS installed base was 567 total systems, a 24 increase from the same period in 2019. Achieved key reimbursement progress for Deep TMS in major depressive disorder. Received multiple new positive coverage decisions, including reduced prior treatment failures to qualify for Deep TMS.With most clinics having now reopened, we see patients steadily returning for Deep TMS treatments, stated Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. As mental health challenges have dramatically risen throughout the course of the ongoing COVID-19 pandemic, we remain focused on enhancing the awareness of and education about Deep TMS on multiple fronts. We also continue to execute our expense reduction plan in order to ensure our business is appropriately positioned to persevere in the current healthcare environment, while also strengthening our long-term growth prospects. We are proud of the resilience and commercial success our business has demonstrated under challenging circumstances, including sequential revenue growth of 16, and expect that significant momentum in our business will emerge once the impact of COVID-19 subsides.Second Quarter 2020 Financial Results Total revenues for the second quarter of 2020 totaled 4.8 million, compared with 5.7 million for the second quarter of 2019, a decrease of 15. Quarterly recurring lease revenues were 3.4 million, representing an increase of 4 over the second quarter of 2019, and comprised 70 of total revenues. Gross margin for the second quarter of 2020 was 79, an increase when compared to second quarter 2019 gross margin of 76, which resulted from lower manufacturing overhead costs in the quarter. Operating expenses for the quarter totaled 4.0 million, compared with 7.0 million for the second quarter of 2019. The decrease is in-line with the Companys efforts to enhance efficiency and to lower operational expenses in light of the financial impact of COVID-19. Operating loss for the quarter was 0.2 million, compared with an operating loss of 2.7 million for the same period in 2019. As of June 30, 2020, the Company had cash and short-term investments of approximately 17.8 million, compared to 21.9 million at December 31, 2019, reflecting a cash use of 4.1 million for the first half of 2020 resulting from operating losses and timing of inventory deliveries from vendors. Conference Call and WebcastBrainsWays management will host a conference call on Wednesday, August 12, 2020, at 8:30 a.m. Eastern Time to discuss these results and answer questions.Wednesday, August 12, at 8:30 AM Eastern Time:Date:Wednesday, August 12, 2020 Time:8:30 AM Eastern Time United States:877-407-3982 Israel:1 809 406 247 International:201-493-6780 Conference ID:13706952 Webcast: To listen to a live webcast, please visit the Investors section of the BrainsWay website at Please access the Companys website at least 10 minutes ahead of the conference call to register. The webcast replay will be available on the website for two weeks following the completion of the call.About BrainsWay BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Companys proprietary Deep Transcranial Magnetic Stimulation Deep TMS technology for the treatment of major depressive disorder MDD and obsessive-compulsive disorder OCD, for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration FDA in 2013 for MDD and in 2018 for OCD. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words intends, may, will, plans, expects, anticipates, projects, predicts, estimates, aims, believes, hopes, potential or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching andor successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Companys anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, andor inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Companys intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, and the effect of the global COVID-19 health pandemic on our business and continued uncertainty and market impact relating thereto.Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading Risk Factors in the Companys filings with the U.S. Securities and Exchange Commission.Contacts: BrainsWay: Judy Huber SVP and Chief Financial Officer Bob Yedid LifeSci Advisors 646-597-6989 BRAINSWAY LTD.CONSOLIDATED STATEMENTS OF FINANCIAL POSITIONU.S. dollars in thousands except share and per share data June 30, December 31, 2020 2019 Unaudited Audited ASSETS CURRENT ASSETS: Cash and cash equivalents17,613 21,674 Shortterm deposits 221 221 Trade receivables, net 5,148 5,507 Other accounts receivable 1,201 1,427 24,183 28,829 NONCURRENT ASSETS: Longterm deposit 161 168 Leased systems 5,314 5,491 System components and other property and equipment 5,537 4,248 11,012 9,907 35,195 38,736 LIABILITIES AND EQUITY CURRENT LIABILITIES: Trade payables2,055 1,320 Other accounts payable 2,939 3,379 Deferred revenues 1,533 1,305 Liability in respect of research and development grants 998 714 7,525 6,718 NONCURRENT LIABILITIES: Deferred revenues and other liabilities 1,959 2,431 Liability in respect of research and development grants 5,067 5,367 7,026 7,798 EQUITY: Share capital 233 233 Share premium 95,108 93,649 Sharebased payment 3,413 4,435 Adjustments arising from translating financial statements from functional currency to presentation currency 2,188 2,188 Accumulated deficit 75,922 71,909 20,644 24,220 35,195 38,736 BRAINSWAY LTD.CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSSU.S. dollars in thousands except share and per share data Six months ended Three months ended June 30, June 30, 2020 2019 2020 2019 Unaudited Revenues8,977 10,877 4,820 5,695 Cost of revenues 2,007 2,534 992 1,376 Gross profit 6,970 8,343 3,828 4,319 Research and development expenses, net 2,836 4,154 1,041 2,362 Selling and marketing expenses 5,891 6,116 2,178 3,278 General and administrative expenses 2,079 2,383 824 1,380 Total operating expenses 10,806 12,653 4,043 7,020 Operating loss 3,836 4,310 215 2,701 Finance expense income, net 130 908 179 672 Loss before income taxes 3,706 5,218 394 3,373 Income taxes 307 162 177 100 Net loss and total comprehensive loss4,013 5,380 571 3,473 Basic and diluted net loss per share0.18 0.29 0.03 0.17 BRAINSWAY LTD.CONSOLIDATED STATEMENTS OF CASH FLOWSU.S. 